Orciprenaline


Generic Medicine Info
Indications and Dosage
Oral
Bronchospasm
Adult: For the treatment of reversible cases that may occur in association with bronchitis and emphysema. Dosage is individualised according to patient response. 20 mg 3-4 times daily.
Child: 6-9 years or weighing <27 kg: 10 mg 3-4 times daily; >9 years or weighing ≥27 kg: Same as adult dose.

Oral
Bronchial asthma
Adult: Dosage is individualised according to patient response. 20 mg 3-4 times daily.
Child: 6-9 years or weighing <27 kg: 10 mg 3-4 times daily; >9 years or weighing ≥27 kg: Same as adult dose.
Administration
May be taken with or without food.
Contraindications
Pre-existing cardiac arrhythmias associated with tachycardia.
Special Precautions
Patient with CV disease (e.g. ischaemic heart disease, hypertension, cardiac arrhythmias), hyperthyroidism, diabetes mellitus, glaucoma, hypokalaemia, or seizures. Not recommended for routine or long-term daily use for the management of acute asthma. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Immediate hypersensitivity reactions (e.g. urticaria, rash, bronchospasm, angioedema), changes in systolic and diastolic blood pressure.
Cardiac disorders: Tachycardia, palpitations.
Gastrointestinal disorders: Nausea, diarrhoea.
Musculoskeletal and connective tissue disorders: Tremor.
Nervous system disorders: Headache, nervousness, dizziness, insomnia, fatigue.
Respiratory, thoracic and mediastinal disorders: Exacerbation of asthma.
Inhalation/Respiratory/PO: C
Monitoring Parameters
Monitor blood pressure, heart rate, pulmonary function tests (e.g. forced expiratory volume in 1 second [FEV1], peak flow), serum glucose, K, and CNS stimulation.
Overdosage
Symptoms: Arrhythmias, angina, hypertension or hypotension, palpitations, nervousness, tremor, headache, dry mouth, nausea, malaise, fatigue, dizziness, and insomnia. Management: Symptomatic treatment.
Drug Interactions
Enhanced adverse effect with other sympathomimetic agents, MAOIs, and TCAs. Diminished bronchodilatory effect with non-selective β-blockers (e.g. propranolol).
Action
Description: Orciprenaline is a bronchodilator which exerts its effect by stimulating the β-adrenergic receptors causing an increased conversion of ATP to 3'-5'-cyclic adenosine monophosphate(cAMP), resulting to bronchial smooth muscle relaxation.
Synonym: metaproterenol.
Onset: Approx 30 minutes (bronchodilation).
Duration: Approx 2-6 hours.
Pharmacokinetics:
Absorption: Well absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1 hour. Bioavailability: Approx 40%.
Metabolism: Undergoes extensive first-pass metabolism in the liver.
Excretion: Via urine (as glucuronic acid conjugates).
Chemical Structure

Chemical Structure Image
Orciprenaline

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4086, Metaproterenol. https://pubchem.ncbi.nlm.nih.gov/compound/Metaproterenol. Accessed June 24, 2021.

Storage
Store below 30°C. Protect from light.
ATC Classification
R03CB03 - orciprenaline ; Belongs to the class of adrenergics for systemic use, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
References
Anon. Metaproterenol (Briggs Drugs in Pregnancy and Lactation). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/06/2021.

Anon. Orciprenaline (Metaproterenol). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/06/2021.

Buckingham R (ed). Orciprenaline sulfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 14/06/2021.

Metaproterenol Sulfate Syrup (Brant Ranch Prepack). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 17/06/2021.

Metaproterenol Sulfate Syrup (Lannett Company, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 14/06/2021.

Metaproterenol. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 17/06/2021.

Disclaimer: This information is independently developed by MIMS based on Orciprenaline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in